
Two-Week Rally, Fed Pressure, Dalio Doubles Down 12/8/25
Morning Call
00:00
Small/Mid-Cap Rally Case and Biotech Pick
Aaron Gibbs favors small and mids for 2026, highlighting Neurocrine for FDA approvals and growth potential.
Play episode from 43:15
Transcript


